江油地区儿童社区获得性肺炎病原学分析

目的了解江油地区社区获得性肺炎病原体分布情况,为经验治疗提供依据。方法对1 995例大于或等于2岁的社区获得性肺炎患儿留取呼吸道分泌物进行细菌培养,同时采用聚合酶链反应检测非典型病原体。结果 1 995例患儿病原学检测阳性426例(21.35%),其中常见细菌阳性324例(16.24%),病原菌中以肺炎链球菌为主,其次为阴沟肠杆菌、肺炎克雷伯菌及肺炎克雷伯菌。非典型病原体102例(5.11%),包括肺炎支原体、细菌合并肺炎支原体感染及肺炎衣原体等。结论肺炎链球菌是江油地区社区获得性肺炎的主要致病菌。     

成人非典型社区获得性肺炎患者病原体感染情况分析

目的分析肺炎支原体(MP)等经典微生物引起的非典型肺炎患者的实验室检查结果,为临床诊治提供参考。方法采用实时荧光定量聚合酶链反应(qPCR)检测188例成人社区获得性肺炎患者急性期咽拭子和/或痰液样本中的MP、肺炎衣原体和嗜肺军团菌,分析每位患者的临床资料、实验室指标、影像学检查结果。结果MP核酸检测阳性41例(21.8%),肺炎衣原体核酸检测阳性1例(0.5%),未检出嗜肺军团菌;细菌培养阳性23例(12.23%)。MP阳性患者年龄较阴性患者小,较少伴有基础疾病,肺部以单侧受累为主,其他临床症状和实验室相关指标差异均无统计学意义。秋季、冬季MP阳性率明显高于春季、夏季(P<0.05)。结论MP是成人社区获得性肺炎的主要病原体,qPCR对MP急性感染的早期诊断具有明显的优势。     

Clinical characteristics of severe community-acquired pneumonia among younger patients: An analysis of 18 years at a community hospital

Unlike elderly patients with community-acquired pneumonia whose outcomes are markedly affected by their background characteristics, it appears that the severity of the infection itself contributes to outcomes in younger patients with community-acquired pneumonia. In order to identify clinical characteristics of severe community-acquired pneumonia in younger patients under 60 years old, among such cases prospectively collected at our hospital over a period of 18 years, those meeting the criteria for severe community-acquired pneumonia, as defined in the Infectious Diseases Society of America/American Thoracic Society Guidelines for community-acquired pneumonia, were retrospectively examined and compared to elderly patients with severe community-acquired pneumonia. Younger patients with severe pneumonia accounted for 12.9% of younger hospitalized patients. Although the incidence of severe pneumonia in younger patients was lower than that in elderly patients, its severity may be underestimated by severity assessment based on the conventional guidelines. Thus, attention is required. While Streptococcus pneumoniae and Legionella species were important causative pathogens, atypical pathogens and viruses were also frequently detected. There were only 11 deaths over a period of 18 years. Based on multivariate analysis, the risk factors for aggravation of community-acquired pneumonia among younger patients were age 50 years or older, diabetes mellitus, chronic liver disease, and Legionella pneumonia. Although the mortality rate from community-acquired pneumonia is extremely low in previously healthy younger patients, outcomes might be poor for patients with underlying diseases and those with rapid progression. Multimodal treatments including respiratory management may be appropriate.     

Does cytomegalovirus play a role in community-acquired pneumonia?

Cytomegalovirus (CMV) is recognized as an important pathogen in the immuno-suppressed patient. Sporadic case reports of cytomegalovirus community-acquired pneumonia have appeared. We studied 443 patients with community-acquired pneumonia requiring hospitalization to define the role of cytomegalovirus in this illness. Four patients (0.9%) had good evidence that cytomegalovirus caused their pneumonia: 2 had the virus isolated from pulmonary tissue and 2 had cytomegalovirus inclusion bodies visualized in this tissue. An additional 14 patients had serologic evidence (a fourfold rise in the complement fixation tests) of cytomegalovirus infection. Analysis of these 18 patients suggest, that cytomegalovirus plays a role in community-acquired pneumonia. Six (33%) of the patients were immunosuppressed. Six others had concomitant infections: Chlamydia trachomatis (3); Epstein-Barr virus and M. pneumoniae (1); and bacteremia with Group B streptococcus and Bacteroides fragilis plus Eubacterium lentum (1 each). Seven patients (39%) required assisted ventilation, four of whom developed secondary bacterial pneumonia. Five (28%) died. Only two patients had a clinical and radiographic picture suggestive of a viral illness as a cause of the pneumonia. Three patients had atypical lymphocytes in their peripheral blood film. We found that the prevalence of complement fixing antibody to cytomegalovirus increased with age. Such antibody was lacking among those in the 16-20 year group while it peaked at 65% for males and at 78% for females ages 91-100 years. Despite the fact that 42.2% of the adults lacked antibody to cytomegalovirus, community-acquired pneumonia due to this virus is uncommon and does not justify routine serological testing for such infection among patients with community-acquired pneumonia.     

Concurrent community-acquired pneumonia with Legionella pneumophila and Streptococcus pneumoniae

Both Streptococcus pneumoniae and Legionella pneumophila are well defined causes of community-acquired pneumonia, and may be associated with substantial mortality. Optimal therapy consists of penicillin for the former organism and erythromycin for the latter. We have presented a case of pneumonia caused by simultaneous infection with both of these agents. Organisms were recovered either from blood or lung tissue. This case carries important implications for treatment of community-acquired pneumonia, and conceivably could explain some of the mortality that continues to be seen with pneumococcal pneumonia.     

Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia. During the past decade, the prevalence of penicillin resistance in S pneumoniae has increased dramatically, with resistance rates approaching 45% in some areas of the United States. Streptococcus pneumoniae has also acquired resistance to other commonly used antimicrobials, including cephalosporins, macrolides, and trimethoprim-sulfamethoxazole. While vancomycin and the newer quinolones are currently highly active against most strains of S pneumoniae, reduced susceptibilities to these agents have been identified in some strains. Prior use of antimicrobial agents is the major risk factor for colonization and infection with antibiotic-resistant strains. beta-Lactam antibiotics remain the treatment of choice for infections caused by susceptible S pneumoniae. The optimum therapy for penicillin-resistant strains remains unclear. Appropriate empirical therapy for patients with community-acquired pneumonia depends in part on the community-specific resistance patterns of S pneumoniae to various antibiotics. In this article, we provide an overview of the development of S pneumoniae resistance to commonly used antibiotics and discuss the implications of the development of resistance on treatment decisions.     

Pneumonia. Patient profiles, choice of empiric therapy, and the place of third-generation cephalosporins.

Choosing appropriate antimicrobial therapy for patients with pneumonia requires knowledge of the etiologic agents seen in specific kinds of patients at specific times and places. For community-acquired pneumonia, there is an important difference in the agents seen in the normal and the compromised host. The normal host most often presents with viral, mycoplasmal, or pneumococcal pneumonia. The exact place of Chlamydia pneumoniae is still under study. A normal host who aspirates is at risk of anaerobic pneumonia. Normal hosts with influenza may acquire superinfection with Streptococcus pneumoniae, Haemophilus influenzae, or Staphylococcus aureus. Under specific epidemiologic conditions, community-acquired pneumonia may be due to Legionella species, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Chlamydia psittaci, a mycotic agent, or tuberculosis. Patients with chronic bronchitis and emphysema are predisposed to H. influenzae, Moraxella catarrhalis, and S. pneumoniae infections. HIV-infected patients are likely to have Pneumocystis carinii pneumonia and pneumonia due to cytomegalovirus, S. pneumoniae, and H. influenzae. Patients with diabetes, nursing-home patients, hospitalized patients, immuno-compromised patients, and patients with recent antibiotic therapy are predisposed to pneumonia due to Gram-negative aerobic bacilli of enteric and environmental origin. Initial therapy should be directed at the likely organism or organisms based on hospital susceptibility surveillance. In the normal host with community-acquired pneumonia, the therapy will often be penicillin G or erythromycin. In the patient predisposed to Gram-negative pneumonia, a third-generation cephalosporin with or without an aminoglycoside is the usual choice.     

Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review

Quinolones are currently used as empirical therapy for treatment of community-acquired lower respiratory infections as they are effective against a broad range of conventional bacterial and 'atypical' pathogens, including Chlamydia pneumoniae. C. pneumoniae is estimated to be associated with 10-20% of community-acquired pneumonia in adults, and has recently been suggested to play a role in several non-respiratory conditions, including atherosclerosis. The newer, third-generation quinolones have enhanced activity against Gram-positive bacteria, including Streptococcus pneumoniae, and prolonged serum half-lives that permit once-daily dosing. Although gemifloxacin (SB-265805) and other new quinolones have good activity against C. pneumoniae in vitro, practically all published treatment studies have relied on serological diagnosis. Consequently, the microbiological efficacy of these agents in human infection has not been assessed. This paper reviews what is known to date of the in vivo microbiological efficacy of the quinolones against C. pneumoniae, and demonstrates the importance of assessing this parameter when evaluating the clinical utility of these agents in C. pneumoniae infection.     

Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: Postmarketing surveillance in Japan

We performed a postmarketing surveillance study to determine the efficacy and safety of the oral quinolone antibacterial agent garenoxacin (Geninax^® Tablets 200 mg) against atypical pneumonia.Between October 2009 and July 2011, patients with community-acquired pneumonia visited 26 facilities in Japan; we collected survey forms from 105 of these patients who were suspected of having atypical pneumonia based on the Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults. We examined the safety in 105 patients and the efficacy in 71 patients.1. The efficacy rates among patients suspected of having atypical pneumonia and those with a confirmed diagnosis of atypical pneumonia were 94.8% (55/58 patients) and 92.3% (12/13 patients), respectively. The efficacy rate was 4/4 for patients in whom Chlamydophila pneumoniae was detected (including 1 patient with a polymicrobial infection with another bacterial strain) and 90% (9/10 patients) for patients in whom Mycoplasma pneumoniae was detected (garenoxacin was ineffective in 1 of 2 patients with a polymicrobial infection with another bacterial strain).2. The incidence of adverse drug reactions (including abnormal laboratory tests) was 4.8% (5/105 patients). Among the adverse drug reactions, gastrointestinal disorders, infection and infestation, nervous system disorder, and skin and subcutaneous tissue disorder were observed in 2.9% of patients (3/105), 1.0% (1/105), 1.0% (1/105), and 1.0% (1/105), respectively.In conclusion, garenoxacin showed an efficacy rate of greater than 90% for suspected atypical pneumonia and confirmed atypical pneumonia. Garenoxacin is considered to be useful in daily practice.     

北京部分地区成年患者社区获得性肺炎的病原学及耐药性分析

目的调查研究北京部分地区成年患者社区获得性肺炎的病原学分布及耐药性情况。方法收集389例成年社区获得性肺炎患者的痰液及385例血液标本。痰细菌培养阳性及肺炎支原体和衣原体的血清学试验阳性结果作为感染指征;细菌药敏试验采用纸片扩散法。结果 389例痰液标本中共培养分离出171株细菌,其中最主要的是肺炎链球菌（34/171）,其次是肺炎克雷伯菌（29/171）及金黄色葡萄球菌（22/171）。对385例患者进行非典型病原菌的血清学检测,分别检出104例肺炎支原体和32例肺炎衣原体。分离的肺炎链球菌对红霉素及青霉素的耐药率分别为70.6%和41.2%。结论成年CAP患者中感染率居前3位的细菌为肺炎链球菌、肺炎克雷伯菌及金黄色葡萄球菌。同样,也存在着大量的非典型病原菌感染及混合感染。除了肺炎链球菌对大环内酯类的耐药率较高外,主要致病性细菌的耐药率普遍较低。     

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

Community-acquired pneumonia occurs 3 to 4 million times per year in the United States, accounting for about 500,000 hospitalizations annually. Empiric treatment is usually instituted because of a lack of early organism-specific diagnostic tests. This study compared empiric therapy with ofloxacin to standard antibiotic regimens (usually a beta-lactam with or without a macrolide) for patients hospitalized for community-acquired pneumonia. Therapy was administered to 298 patients (146 receiving ofloxacin and 152 receiving standard therapy); 227 patients (ofloxacin, 109; standard treatment, 118) were evaluable for treatment efficacy. The most common pyogenic respiratory pathogens were Haemophilus influenzae (30 isolates) and Streptococcus pneumoniae (24 isolates). There was evidence of infection with either Mycoplasma pneumoniae (38 patients), Chlamydia pneumoniae (40 patients), or a Legionella sp. (8 patients) in a total of 79 patients (35%). The clinical success rates were similar in both groups among evaluable patients (92%, ofloxacin; 87%, standard therapy) and among patients with atypical respiratory pathogens (88%, ofloxacin; 81%, standard therapy). The mean numbers (+/- the standard deviations) of intravenous doses of antibiotics were 7.5 +/- 8.0 in the ofloxacin group and 18.4 +/- 18.5 in the standard therapy group (P < 0.001); the mean number of oral doses of ofloxacin per patient was 19.7 +/- 11.2, compared with 30.2 +/- 16.0 oral antibiotic doses in the standard therapy group (P < 0.001). All treatments were well tolerated and associated with no significant clinical or laboratory abnormalities. The findings of this study indicate that ofloxacin is active against traditional bacterial pathogens as well as the major atypical respiratory pathogens. When given as monotherapy for the empiric treatment of community-acquired pneumonia, ofloxacin is as effective as standard antimicrobial therapy.     

Community-acquired pneumonia in infants and children

Community-acquired pneumonia is one of the most common serious infections in children, with an annual incidence of 34 to 40 cases per 1,000 children in Europe and North America. When diagnosing community-acquired pneumonia, physicians should rely mainly on the patient's history and physical examination, supplemented by judicious use of chest radiographs and laboratory tests as needed. The child's age is important in making the diagnosis. Pneumonia in neonates younger than three weeks of age most often is caused by an infection obtained from the mother at birth. Streptococcus pneumoniae and viruses are the most common causes in infants three weeks to three months of age. Viruses are the most frequent cause of pneumonia in preschool-aged children; Streptococcus pneumoniae is the most common bacterial pathogen. Mycoplasma pneumoniae and Chlamydia pneumoniae often are the etiologic agents in children older than five years and in adolescents. In very young children who appear toxic, hospitalization and intravenous antibiotics are needed. The symptoms in outpatients who present with community-acquired pneumonia can help determine the treatment. Knowing the age-specific causes of bacterial pneumonia will help guide antibiotic therapy. Childhood immunization has helped decrease the incidence of invasive Haemophilus influenzae type B infection, and the newly introduced heptavalent pneumococcal vaccine may do the same for Streptococcus pneumoniae infections.     

儿童社区获得性肺炎的血清降钙素原与超敏C反应蛋白的相关性分析

目的 探讨血清降钙素原(PCT)与超敏C反应蛋白(hs-CRP)检测结果 在儿童社区获得性肺炎中的相关性.方法 112例儿童社区获得性肺炎患者入院后24 h内检测PCT、hs-CRP,并进行相关性分析.结果 细菌性肺组炎PCT与hs-CRP呈正相关(r=0.855,P<0.01),支原体肺炎组和病毒性肺炎组的PCT与hs-CRP均无相关性(P>0.05),细菌性肺炎组PCT和hs-CRP的阳性率明显高于支原体肺炎组和病毒性肺炎组(P<0.05).支原体肺炎组hs-CRP阳性率与病毒性肺炎组比较差异有统计学意义(P<0.05).结论 细菌性肺炎患者PCT 与hs-CRP检测结果 呈正相关,联合检测有助于对社区获得性肺炎的鉴别诊断及合理用药.     

Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance?

Patients hospitalized with community-acquired pneumonia caused by S. pneumoniae strains with intermediate susceptibility to penicillin according to the conventional definition respond well to treatment with adequate doses of beta-lactam antibiotics. All studies currently available comparing mortality between patients with pneumonia caused by nonsusceptible and susceptible pneumococci agree that resistance of MIC 2 mg/L is not associated independently with an increased mortality. Most but not all studies could not prove an effect of microbial resistance on morbidity. There are data suggesting, however, that pneumococcal pneumonia caused by highly resistant strains (MIC > or = 4 mg/L) does affect the outcome. Pneumococcal resistance remains a matter of concern. Most reports show an increase not only of resistance rates, but also of the proportion of highly resistant strains. The selection of initial empirical antimicrobial treatment of patients with community-acquired pneumonia should be performed judiciously. Because the serum and pulmonary levels achieved with penicillin or related drugs are several times higher than the MICs of most strains, pneumonias caused by S. pneumoniae currently defined as not susceptible to penicillin should respond well to treatment with a beta-lactam antibiotic, used in optimal doses. Consequently, there is no reason fundamentally to change the current approach to initial empiric antimicrobial treatment of patients with community-acquired pneumonia. Nevertheless, increases in resistance to macrolides may prompt a limited use of these drugs in the outpatient setting. In any case, treatment failures may occur at higher levels of resistance, and a change in the definition of susceptibility categories toward higher cutoffs for S. pneumoniae seems to be reasonable.     

Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia

BACKGROUND: The value of elevated serum procalcitonin concentration for differentiating between typical and atypical community-acquired pneumonia was assessed and compared with other parameters that are usually used in clinical practice. PATIENTS AND METHODS: Thirty consecutive adult patients with community-acquired bacterial pneumonia admitted to the Department of Infectious Diseases, University Medical Center Ljubljana, Slovenia, were included in this prospective study. Only those patients for whom the etiology of bacterial pneumonia was confirmed participated in the study. RESULTS: The median serum procalcitonin level in patients with typical pneumonia was 7.64 ng/ml (range 0.26-63.16) and in the group with atypical pneumonia 0.80 ng/ml (range 0.13-34.90). A significant difference between the typical and atypical pneumonia groups was found only for the procalcitonin serum concentration on admission. The standard laboratory markers of bacterial infections, such as C-reactive protein, total leukocyte count and immature polymorphonuclear cells, did not discriminate between typical and atypical etiology. Median procalcitonin levels were significantly higher among patients with bacteremic pneumonia. CONCLUSIONS: Determination of the procalcitonin level may provide useful additional diagnostic information on the etiology of pneumonia and could have a crucial influence on the initial antimicrobial therapy.     

Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns

Current treatment guidelines for community-acquired respiratory tract infections no longer depend solely on the characteristics of the patient and the clinical syndrome, but on those of the offending pathogen, including presence and level of antimicrobial resistance. The most common respiratory tract pathogens known to cause acute bacterial rhinosinusitis (ABRS) and community-acquired pneumonia (CAP) include Streptococcus pneumoniae and Haemophilus influenzae. The prevalence of antimicrobial resistance, especially b-lactum and macrolide resistance, among S pneumoniae and H influenzae has increased dramatically during the past 2 decades, diminishing the activity of many older antimicrobials against resistant organisms. A pharmacokinetically enhanced formulation of amoxicillin/clavulanate has been developed to fulfill the need for an oral b-lactam antimicrobial that achieves a greater time that the serum drug concentration exceeds the minimum inhibitory concentration (T > MIC) of antimicrobials against pathogens than conventional formulations to improve activity against S pneumoniae with reduced susceptibility to penicillin. The b-lactamase inhibitor clavulanate allows for coverage of b-lactamase-producing pathogens, such as H influenzae and M catarrhalis. This article reviews the rationale for, and evolution of, oral amoxicillin clavulanate for ABRS and CAP     

Community-acquired pneumonia: etiology, diagnosis, and treatment

Pneumonia is an important cause of morbidity and mortality. A variety of conditions that damage the airways and weaken host defense mechanisms increase the susceptibility of the individual to bacterial colonization of the pulmonary tree. Because the clinician frequently cannot determine the etiologic agent, pneumonia is often treated empirically. Cefonicid, a long-acting cephalosporin, is a useful and cost-effective antibiotic that is active against many of the common pathogens that cause community-acquired pneumonia, such as Streptococcus pneumoniae and Haemophilus influenzae. It is also active against less common community-acquired pathogens, such as Klebsiella pneumoniae, Escherichia coli, and some anaerobic mouth flora. Erythromycin is useful when Mycoplasma or Legionella species are suspected. Cefonicid's demonstrated safety and efficacy, its low cost, and its long half-life, permitting once-daily dosing, make this antibiotic an ideal parenteral choice for empiric therapy of community-acquired pneumonia.     

Validation of JRS atypical pneumonia score in patients with community-acquired Chlamydia psittaci pneumonia

IntroductionThe Japanese Respiratory Society (JRS) atypical pneumonia score is a useful tool for the rapid presumptive diagnosis of atypical pneumonia. We investigated the clinical features of community-acquired pneumonia (CAP) due to Chlamydia psittaci and validated the JRS atypical pneumonia score in patients with C. psittaci CAP.MethodsThis study was conducted at 30 institutions and assessed a total of 72 sporadic cases with C. psittaci CAP, 412 cases with Mycoplasma pneumoniae CAP, and 576 cases with Streptococcus pneumoniae CAP.ResultsSixty-two of 72 patients with C. psittaci CAP had a history of avian exposure. Among the six parameters of the JRS score, matching rates of four parameters were significantly lower in the C. psittaci CAP than the M. pneumoniae CAP in the following parameters: age <60 years, no or minor comorbid illness, stubborn or paroxysmal cough, and absence of chest adventitious sounds. The sensitivity of the diagnosis of atypical pneumonia in patients with C. psittaci CAP was significantly lower than the M. pneumoniae CAP (65.3% and 87.4%, p < 0.0001). When the diagnostic sensitivity was analyzed for different ages, the diagnostic sensitivities for the C. psittaci CAP were 90.5% for non-elderly patients and 30.0% for elderly patients.ConclusionsThe JRS atypical pneumonia score is a useful tool for distinguishing between C. psittaci CAP and bacterial CAP in patients aged <60 years, but not in patients aged ≥60 years. A history of avian exposure in middle-aged patients with normal white blood cell count may be suggestive of C. psittaci pneumonia.     

Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay

A multiplex real-time PCR assay for the detection of Mycoplasma pneumoniae (MP181), Chlamydia (Chlamydophila) pneumoniae (CP-Arg), Legionella spp. (Pan-Leg), and the human RNase P (RNase P) gene was developed for rapid testing of atypical bacterial respiratory pathogens in clinical specimens. This method uses 4 distinct hydrolysis probes to detect 3 leading causes of community-acquired pneumonia. The assay was evaluated for specificity and sensitivity by testing against 35 related organisms, a dilution series of each specific target and 197 clinical specimens. Specificity testing demonstrated no cross-reactivity. A comparison to previously validated singleplex real-time PCR assays for each agent was also performed. The analytical sensitivity for specific pathogen targets in both the singleplex and multiplex was identical (50 fg), while efficiencies ranged from 82% to 97% for the singleplex assays and from 90% to 100% for the multiplex assay. The clinical sensitivity of the multiplex assay was improved for the Pan-Leg and CP-Arg targets when compared to the singleplex. The MP181 assay displayed equivalent performance. This multiplex assay provides an overall improvement in the diagnostic capability for these agents by demonstrating a sensitive, high-throughput and rapid method. This procedure may allow for a practical and efficient means to test respiratory clinical specimens for atypical pneumonia agents in health care settings and facilitate an appropriate public health response to outbreaks.     

Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program

The SENTRY Antimicrobial Surveillance Program has been monitoring the activity of commonly prescribed and novel antimicrobial agents on a global scale from 1997 to the present. Specific objectives have documented the key resistance rates among pathogens from both patients hospitalized with pneumonia and those diagnosed with community-acquired pneumonia. Hemophilus influenzae and Streptococcus pneumoniae are common pathogens in both of these patient populations and the susceptibility profiles for these two species were compared to distinguish potential differences that may be evident in North American surveillance (1997-2001). A total of 6,515 isolates of S. pneumoniae and 6,726 H. influenzae strains were tested using reference broth microdilution methods at a monitoring center. Ampicillin resistance was approximately 25% among H. influenzae isolates and did not significantly differ between strains from community-acquired infections or hospitalized patients. beta-lactamase-negative ampicillin resistant strains and fluoroquinolone refractory strains were rare (0.3 and 相似文献